Table 3.
Comparison between the characteristics of the 18 p53abn patients and the 352 p53wt patients.
| Characteristics | p53abn | p53wt | p Value * |
|---|---|---|---|
| Patients (%) | Patients (%) | ||
| All cases | 18 (100%) | 352 (100%) | |
| Age (years) | |||
| Average (range) | 65 (49–81) | 63 (32–86) | p = 0.721 |
| Parity | |||
| Previous pregnancies | 18 (100%) | 272 (77.3%) | |
| Nulliparous | 0 (0%) | 80 (22.7%) | p = 0.078 |
| Menopause | |||
| Yes | 18 (100%) | 304 (86.4%) | |
| No | 0 (0%) | 48 (13.6%) | p = 0.294 |
| Body Mass Index | |||
| Underweight | 0 (0%) | 3 (0.9%) | |
| Normal weight | 7 (38.9%) | 69 (19.6%) | |
| Overweight | 10 (55.6%) | 244 (69.3%) | |
| Unknown | 1 (5.5%) | 36 (10.2%) | p = 0.071 |
| Family history of gynecological cancer | |||
| EC | 7 (38.9%) | 2 (0.6%) | |
| OC | 0 (0%) | 11 (3.1%) | |
| BC | 0 (0%) | 19 (5.4%) | |
| No | 11 (61.1%) | 262 (74.4%) | |
| Unknown | 0 (0%) | 58 (16.5%) | p = 0.0001 |
| Symptoms at diagnosis | |||
| Vaginal bleeding | 16 (88.8%) | 304 (86.4%) | |
| Abdominal pain/swelling | 0 (0%) | 15 (4.2%) | |
| Others | 2 (11.2%) | 33 (9.4%) | p = 0.962 |
| Preoperative histological diagnosis | |||
| Endometrioid G1-2 | 16 (88.8%) | 295 (83.8%) | |
| Endometrial hyperplasia | 2 (11.2%) | 32 (9.1%) | |
| Other histology | 0 (0%) | 8 (2.3%) | |
| Not carried out | 0 (0%) | 17 (4.8%) | p = 0.881 |
| Pap smear | |||
| Normal | 11 (61.1%) | 183 (51.9%) | |
| Inflammatory | 0 (0%) | 8 (2.3%) | |
| Malignancy | 0 (0%) | 5 (1.4%) | |
| Not a recent analysis (>18 months) | 7 (38.9%) | 156 (44.4%) | p = 0.476 |
| Preoperative radiologic FIGO staging ** | |||
| Stage Ia | 16 (88.8%) | 249 (70.7%) | |
| Stage Ib | 2 (11.2%) | 42 (11.9%) | |
| Stage ≥II | 0 (0%) | 5 (1.4%) | |
| Unknown | 0 (0%) | 56 (16.0%) | p = 0.353 |
| Type of surgery | |||
| PWC, RH + BSO + SLN | 11 (61.1%) | 127 (36.1%) | |
| PWC, RH + BSO + P lymph | 2 (11.1%) | 47 (13.4%) | |
| PWC, RH + BSO + P and PA lymph nodes | 0 (0%) | 5 (1.4%) | |
| PWC, RH + BSO + SLN + P and/or PA lymph | 4 (22.2%) | 10 (2.8%) | |
| PWC, RH + BSO | 1 (5.6%) | 163 (46.3%) | p = 0.0002 |
| Grading | |||
| G1 | 16 (88.9%) | 201 (57.1%) | |
| G2 | 2 (11.1%) | 151 (42.9%) | p = 0.007 |
| MELF pattern | |||
| Absent | 17 (94.4%) | 290 (82.4%) | |
| Present | 1 (5.6%) | 39 (11.1%) | |
| Unknown | 0 (0%) | 23 (6.5%) | p = 0.697 |
| MSH-6 | |||
| Preserved | 15 (83.3%) | 333 (94.6%) | |
| Lost | 3 (16.7%) | 19 (5.4%) | p = 0.051 |
| MSH-2 | |||
| Preserved | 15 (83.3%) | 334 (97.7%) | p = 0.006 |
| Lost | 3 (16.7%) | 8 (2.3%) | |
| PMS-2 | |||
| Preserved | 18 (100%) | 294 (83.5%) | |
| Lost | 0 (0%) | 58 (16.5%) | p = 0.193 |
| MLH-1 | |||
| Preserved | 18 (100%) | 297 (84.5%) | |
| Lost | 0 (0%) | 55 (15.5%) | p = 0.231 |
| ER (%) | |||
| Negative | 1 (5.6%) | 9 (2.6%) | |
| Positive <25% | 1 (5.6%) | 37 (10.5%) | |
| Positive 25–49% | 0 (0%) | 36 (10.2%) | |
| Positive ≥50% | 16 (88.8%) | 270 (76.7%) | p = 0.671 |
| PgR (%) | |||
| Negative | 1 (5.6%) | 17 (4.8%) | |
| Positive <25% | 1 (5.6%) | 34 (9.6%) | |
| Positive 25–49% | 0 (0%) | 65 (18.5%) | |
| Positive ≥50% | 16 (88.8%) | 236 (67%) | p = 0.401 |
| POLE | |||
| Not carried out | 13 (72.2%) | 327 (92.9%) | |
| Mutated | 0 (0%) | 0 (0%) | |
| Nonmutated | 5 (27.8%) | 25 (7.1%) | p = 0.007 |
OC = ovarian cancer; BC = bowel cancer; PWC = peritoneal washing cytology. RH = radical hysterectomy. BSO = bilateral salpingo-oophorectomy. SLN = sentinel lymph node biopsy. P = pelvic. PA = para-aortic; ER = estrogen; PgR = progesterone. * = either with ultrasound or CT scan. ** = results are presented without the necessary adjustments for multiple comparisons that would downsize the effect due to the mere descriptive nature of the table and considering that the only data that significatively differ do not influence the final data of the study.